Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial (Q33417361)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial |
scientific article |
Statements
1 reference
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial (English)
1 reference
Peter Hau
1 reference
Michael Weller
1 reference
Wolfgang Wick
1 reference
David A Reardon
1 reference
Astrid Weyerbrock
1 reference
Rafał Tarnawski
1 reference
Alba A Brandes
1 reference
Tejpal Gupta
1 reference
Martin J van den Bent
1 reference
Kenneth D Aldape
1 reference
Rolf-Dieter Kortmann
1 reference
Roger Stupp
1 reference
Thierry Gorlia
1 reference
Sara C Erridge
1 reference
Ulrich Herrlinger
1 reference
Catherine McBain
1 reference
Joerg Christian Tonn
1 reference
Martin J B Taphoorn
1 reference
James Perry
1 reference
Yong-Kil Hong
1 reference
Benoit Lhermitte
1 reference
Torsten Pietsch
1 reference
Danica Grujicic
1 reference
Joachim Peter Steinbach
1 reference
Do-Hyun Nam
1 reference
Chiung-Chyi Shen
1 reference
Nalini Rao
1 reference
László Thurzo
1 reference
Krystyna Adamska
1 reference
Oliver Schnell
1 reference
Thomas Wiegel
1 reference
Chae-Yong Kim
1 reference
Christine Hicking
1 reference
Andriy Markivskyy
1 reference
Martin Picard
1 reference
European Organisation for Research and Treatment of Cancer (EORTC)
1 reference
Canadian Brain Tumor Consortium
1 reference
CENTRIC study team
1 reference
19 August 2014
1 reference
1 reference
Identifiers
1 reference